What changed
Based on reporting by Quiver Quantitative, Yale University’s IRB approved patient recruitment for Parts B and C of Clearmind Medicine’s Phase I/II CMND-100 trial in alcohol use disorder. Yale’s psychiatry department, led by Dr. Anahita Bassir Nia, can now recruit alongside Johns Hopkins and two Israeli medical centres; Clearmind previously reported that all 24 Part A participants completed treatment, with no serious adverse events observed.
Why This Matters
This is an operations milestone, not a treatment breakthrough. Adding Yale gives Clearmind another academic site able to screen and enroll patients, which can turn a promising early safety result into the patient-stage data that actually determines whether CMND-100 has a future.
The crucial distinction is efficacy. CMND-100 is described as a non-hallucinogenic, MEAI-based candidate, but the report offers safety, tolerability and pharmacokinetic work, not proof that it treats alcohol use disorder. For people near Yale who meet the study’s criteria, an investigational enrollment route may become available. For operators watching clinical-stage companies, the next material question is execution: can the network enroll suitable patients and complete the study without operational drag?
Our outlook (informed speculation): Yale likely adds useful screening capacity in the coming weeks, while routine treatment practice remains unchanged until patient-stage findings show more than a workable safety profile.
How the effects could spread
Yale’s approval allows its psychiatry department to begin recruitment for Parts B and C. If the site activates and finds eligible participants, it could reduce the enrollment burden on the other recruiting centres and broaden access to trial screening around Yale.
That additional capacity could help Clearmind move from early dose-escalation work toward patient-stage results. The chain can still break at the least glamorous link: activation, recruitment and retention. An approved site is a door unlocked, not a waiting room already full.
Impact assessment
Clearmind gains a recruitment-capable academic site immediately, potentially improving the programme’s enrollment capacity over the coming weeks. Its advantage depends on whether Yale converts approval into active screening and completed cohorts.
Yale’s psychiatry department gains a defined role in the multicentre study under Dr. Bassir Nia’s leadership. Eligible local patients may gain another route to seek entry into an investigational study, though eligibility and available enrollment slots remain decisive.
Treatment providers may eventually receive new evidence about a non-hallucinogenic candidate if the study progresses. Nothing in the report supports changing routine care today.
Scenarios
Most likely
If Yale activates recruitment and identifies eligible patients, it adds screening and enrollment capacity over the next several weeks to 12 months. That would help the multicentre trial progress while CMND-100 remains investigational, with no immediate change in clinical practice. Evidence of active Yale enrollment and broader cohort progress would support this path; a pause or delay would weaken it.
Upside
If Yale and the existing sites recruit and retain participants efficiently, Clearmind could complete the planned patient-enrollment work sooner and shift operational resources toward analyzing later-stage clinical data within six to 12 months. Rising enrollment, completed cohorts and continued acceptable safety findings would point in that direction.
Downside
If recruitment proves slow or later patient-stage observations require operational changes, Yale’s approval may add little practical speed. Clearmind could need to spend more time on screening, retention or protocol execution before generating useful patient data. Cohort delays, site-expansion needs or new safety constraints would signal that outcome.
What to watch next
- Whether Yale begins actively screening or enrolling patients for Parts B and C in the coming weeks.
- Multicentre enrollment and cohort-completion progress over the next six to 12 months.
- Patient-stage safety and pharmacokinetic findings, which will show whether the programme can continue advancing beyond its reported Part A results.
Comments
No comments yet.